ArticleFrontiers in medicine2026
Plasma exchange and double plasma molecular adsorption system combined with continuous renal replacement therapy for hepatitis B-related liver failure complicated by stage 3 acute kidney injury: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus (HBV)-related liver failure can progress rapidly to neurological and renal dysfunction. In this setting, declining aminotransferase levels may be misleading if hepatic synthetic function and extrahepatic organ function continue to deteriorate. Case presentation: A 27-year-old woman presented with severe fatigue, dark urine, and jaundice. Laboratory testing showed marked hepatocellular injury, coagulopathy, HBV infection markers, and an HBV DNA level of 3.57 × 10⁶ copies/mL. During hospitalization, serum aminotransferase levels declined substantially; however, bilirubin and coagulation abnormalities worsened, serum creatinine increased from 96 μmol/L on day 1 to 825 μmol/L on day 4, and the patient developed hypersomnia and impaired consciousness. The renal deterioration met criteria for stage 3 acute kidney injury. Following multidisciplinary assessment, plasma exchange combined with a double plasma molecular adsorption system was used for liver-directed extracorporeal support, while continuous renal replacement therapy was initiated primarily for severe acute kidney injury and metabolic support. Consciousness, coagulation, liver function, and renal function subsequently improved. The patient left the intensive care unit on day 7, was discharged on day 24, and maintained normal liver and kidney function during follow-up. Conclusion: This case highlights that declining aminotransferase levels do not necessarily indicate clinical recovery in rapidly progressive HBV-related liver failure. Serial assessment of hepatic synthetic function, neurological status, and renal function identified continued multiorgan deterioration and guided timely, indication-based extracorporeal support. The clinical value of this case lies in the decision-making process for coordinated liver and renal support rather than in the novelty of the individual treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.